EAM
Eventide Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.1M | Sell |
125,902
-40,548
| -24% | -$13.2M | 0.72% | 44 |
|
|
2025
Q1 | $44.9M | Sell |
166,450
-73,968
| -31% | -$20M | 0.9% | 38 |
|
|
2024
Q4 | $56.6M | Buy |
240,418
+16,085
| +7% | +$3.79M | 1.03% | 30 |
|
|
2024
Q3 | $61.7M | Buy |
224,333
+137,333
| +158% | +$37.8M | 1.06% | 32 |
|
|
2024
Q2 | $21.1M | Hold |
87,000
| – | – | 0.36% | 88 |
|
|
2024
Q1 | $13M | Hold |
87,000
| – | – | 0.2% | 111 |
|
|
2023
Q4 | $16.7M | Buy |
+87,000
| New | +$16.7M | 0.27% | 96 |
|
|
2018
Q4 | – | Sell |
-62,000
| Closed | -$5.43M | – | 138 |
|
|
2018
Q3 | $5.43M | Hold |
62,000
| – | – | 0.2% | 99 |
|
|
2018
Q2 | $6.11M | Hold |
62,000
| – | – | 0.25% | 89 |
|
|
2018
Q1 | $7.38M | Sell |
62,000
-28,000
| -31% | -$3.33M | 0.35% | 78 |
|
|
2017
Q4 | $11.4M | Hold |
90,000
| – | – | 0.6% | 58 |
|
|
2017
Q3 | $10.6M | Hold |
90,000
| – | – | 0.6% | 57 |
|
|
2017
Q2 | $7.18M | Hold |
90,000
| – | – | 0.45% | 60 |
|
|
2017
Q1 | $4.61M | Hold |
90,000
| – | – | 0.31% | 74 |
|
|
2016
Q4 | $3.37M | Hold |
90,000
| – | – | 0.22% | 82 |
|
|
2016
Q3 | $6.1M | Hold |
90,000
| – | – | 0.37% | 70 |
|
|
2016
Q2 | $4.99M | Hold |
90,000
| – | – | 0.31% | 74 |
|
|
2016
Q1 | $5.65M | Hold |
90,000
| – | – | 0.32% | 70 |
|
|
2015
Q4 | $8.47M | Buy |
90,000
+19,300
| +27% | +$1.82M | 0.42% | 64 |
|
|
2015
Q3 | $5.68M | Buy |
70,700
+25,200
| +55% | +$2.02M | 0.33% | 70 |
|
|
2015
Q2 | $5.45M | Buy |
45,500
+3,600
| +9% | +$432K | 0.3% | 72 |
|
|
2015
Q1 | $4.38M | Buy |
+41,900
| New | +$4.38M | 0.33% | 71 |
|